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1. In recent years considerable efforts have been made to increase the 
evidence base for decision making within the NHS.  Under the NHS R&D 
Programme a sizeable percentage of NHS resources have been spent on 
research, one of the largest programmes of research being in the field of 
health technology assessment. 
2. However, whilst the generation of more research evidence is important, 
mechanisms still need to be developed to increase its use in NHS decision 
making.  The NHS White Paper of 1997 (paragraph 7.5) pointed out that 
“there are unjustifiable variations in the application of evidence on clinical 
and cost-effectiveness”. 
3. The concept of the Health Improvement Programme (HImP) was first 
introduced in “The New NHS. Modern: Dependable” (NHS Executive, 1997).  
This white paper gave the lead responsibility to health authorities to provide 
a framework for health and social care provision through multi-agency 
partnership and in collaboration with the public.  One of the main aims of the 
HImP is to produce action plans based on evidence to address local and 
national priorities.  HImPs cover a three year long cycle and are revised 
annually.  The second phase HImPs ran from April 2000 to April 2003 and 
these are the focus of this project. 
4.  To date, a small number of reviews of HImPs have been conducted (Abbott 
et al, 2000, Arora et at 1999 & 2000, Carruthers et al, 1999) but there has 
been limited exploration of the role of evidence in relation to the HImP, and 
no specific effort has been made to examine whether the HImP has proved 
to be a useful vehicle in arranging provision of care to improve the health of 
the population, given resource constraints. This report explores the 
evidence base of these second phase HImPs with particular reference to 
the contribution of economic evidence. 
 
Methods 
5.  In order to examine the use of evidence in the design of HImPs, a three-
stage project was undertaken.  First, a survey of all English health 
authorities was conducted to elicit HImP leaders’ views on the use of 
evidence in the design of their own HImP.  Second, 10 individuals involved 
in the HImP and who worked for different health authorities were interviewed 
to explore their views on the HImP, the role of evidence and the impact of 
the HImP.  Third, a random sample of 25% of all 2000-2003 HImP 
documents from the health authorities in England were reviewed in order to 
investigate whether the health care priorities chosen reflect government 
objectives and whether there was any evidence of the use of economic 
evidence in the production of the HImP documents. 
Findings 
6. The main findings were that, first, HImPs are seen as having multiple 
objectives.  Whereas the improvement of health is viewed as the prime Use of Economic Evidence in the Design of HImPs  4 
objective, other important objectives are to reduce health inequalities and to 
develop partnerships. 
7.  Second, the notion of evidence is interpreted broadly.  Namely, data drawn 
from classical research studies and published in the literature, do not 
encompass the range of inputs to the design of a HImP.  Many of the inputs 
relate to national guidance and local professional opinion, which in turn 
might be based on data from research studies. 
8. Third, basic concepts of economics are well understood, if not always 
applied.  This is partly because the level of access to economic analyses 
and economics expertise was low.  Even where economic studies did exist, 
it was not clear how they could be interpreted and used. 
9. Fourth, local constraints greatly influence the development of HImPs.   
These constraints include time limitations, lack of certain expertise and the 
need for political acceptability. These often restricted the extent of the 
search for, interpretation and use of economic evidence. 
10.  Finally, most importantly, national guidance from National Service 
Frameworks (NSFs) and the National Institute for Clinical Excellence (NICE) 
is very influential in the design of HImPs.  Given the constraints at the local 
level, national guidance was assumed to have a sound evidence base and 
was usually followed, although sometimes adapted in the light of local 
circumstances.  Therefore, the use of national guidance may be the best 
route to improving the evidence base of HImPs.  
 
Research and policy implications 
11.  The results of this research lend considerable support to a number of 
research and policy implications, many of which are already underway.  The 
main implications are: (i) the evidence base of national guidance should be 
maintained, if not strengthened; (ii) efforts should continue to generate, 
synthesise and disseminate evidence on a national level; (iii) quantifiable 
targets (for health improvement) and the role for evidence in priority setting 
need to be stressed; (iv) the local role in assembling evidence needs to be 
clearly defined and adequately resourced; (v) efforts to educate health care 
professionals in evidence-based medicine and economics should be 
maintained, or strengthened; (vi) more research should be undertaken into 
the cost-effectiveness of broader socio-economic interventions to improve 
health. 
12.  Finally, the research and policy implications of this study also need to be 
reviewed in the light of the recently announced organisational changes in 
the NHS, especially the creation of strategic health authorities and the 
developing role of PCGs/Ts.  In particular, it will be important to ensure that 
PCGs/Ts have the resources and expertise to gather, synthesise and 
interpret evidence, including economic evidence. Use of Economic Evidence in the Design of HImPs 
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1.  Introduction 
 
In recent years considerable efforts have been made to increase the evidence 
base for decision making within the NHS.  Under the NHS R&D Programme a 
sizeable percentage of NHS resources have been spent on research, one of 
the largest programmes of research being in the field of health technology 
assessment.  In addition, institutions such as the NHS Centre for Reviews and 
Dissemination, the Cochrane Collaboration and the National Coordinating 
Centre for Health Technology Assessment have greatly contributed to the 
communication of research findings to the NHS. 
 
The NHS white paper of 1997 (para 7.5) pointed out that “there are unjustifiable 
variations in the application of evidence on clinical and cost-effectiveness” 
(NHS Executive, 1997).  This view is echoed by several surveys of NHS 
decision-makers (Crump et al, 2000, Drummond et al, 1997; Duthie et al, 1999) 
which showed a generally low uptake of available economic evidence and 
identified a number of barriers to its use. 
 
At the national level, the advent of the National Institute of Clinical Excellence 
(NICE) (DH, 1999) provides a vehicle by which clinical and cost-effectiveness 
evidence can be used in decisions about the use of health care interventions, 
either through technology appraisal or clinical guidelines development.   
However, at the local level, within the NHS, it is less clear how appropriate 
evidence (in particular economic evidence) can be brought to bear on NHS 
decisions. 
 
Under the existing structure, many of the decisions about the use of health care 
interventions will increasingly be taken by Primary Care Groups (PCGs) and 
Primary Care Trusts (PCTs).  However, most of these will be too small to have 
a capacity to collect, assimilate and apply evidence.  The health authorities’ 
main mechanism for coordinating health care provision, in partnership with 
PCGs/PCTs, NHS Trusts and other agencies is the Health Improvement 
Programme (HImP).   
 
Therefore, the objective of the research was to study HImPs in order to 
investigate the extent to which evidence, in particular economic evidence, had 
been used in their development. 
 
2.  Policy Background 
 
The HImP was introduced in the White Paper, “The New NHS. Modern: 
Dependable” and was described as “an action programme led by the health 
authority to improve the health and healthcare locally” (NHS Executive, 1997).  
There were 3 main aims of the HImP: (i) to provide a framework for health and 
social care through inter-agency collaboration; (ii) to produce action plans 
based on evidence to address local and national priorities and; (iii) to make a 
programme that involved and was accessible to the public.  Crucially, the 
government moved away from health care as a priority to a new focus on the Use of Economic Evidence in the Design of HImPs  6 
wider agenda of health and this involves a degree of integration between health 
and social services (Griffiths, 1998).  The new approach to provision of care 
provides many opportunities and challenges and the success of such ambitions 
will be seen in the extent to which they can be operationalised in practice and 
the extent to which health does indeed improve. 
 
The HImP was organised as a partnership between each health authority and 
their associated NHS Trusts, PCGs
1 and other primary care professionals, local 
authorities and a number of other local interests including voluntary agencies.  
Every year, each health authority in England is expected to produce a HImP 
document covering a three year time period and the current, third phase of the 
HImP runs from 2001-2004
2.  One important principle underlying the new 
structure has been a “drive to efficiency … so that every pound in the NHS is 
spent to maximise the care for patients” (NHS Executive, 1997).  Guidance on 
HImPs was also provided in “Saving Lives: Our Healthier Nation” and in this 
report it was stated that measures should be been taken to “show that the 
action proposed is based on evidence of what is known to work” (para. 10.18) 
(NHS Executive, 1999). 
 
As part of the HImP, the plan was to bring multiple agencies together through 
joint ventures such as planning and priority setting via the Joint Investment 
Programme and the Primary Care Group Investment Programmes.  Also it was 
envisaged that the HImP would be closely linked to resource allocation and the 
NHS’s annual Service and Financial Framework (SaFF). 
 
The national policy framework was based on three main sources, the national 
priorities guidance (1999), Saving Lives: Our Healthier Nation (NHS Executive, 
1999), and the National Service Frameworks (NSFs).  As part of the white 
paper “Saving Lives”, four priority areas for action were identified, including 
heart disease and stroke, cancer, accidents and mental health with national 
targets set for each. 
 
The NSFs were described in "A First Class Service” as a method of "setting 
standards that will achieve greater consistency in the availability and quality of 
services for a range of major care areas and disease groups” (NHS Executive, 
1998).  Through the NSFs, national standards on specific areas of service or 
disease areas were set up in order to reduce unacceptable variations in care 
and treatment patterns within the NHS in England and Wales (NHS Executive, 
1998).  The second NSF covered coronary heart disease (CHD) (NHS 
Executive, 1998) and the Calman-Hine report provided a similar form of 
direction for cancer services (Calman-Hine, 1995). 
 
Another element of the document "A First Class Service” was to give special 
responsibility to the National Institute of Clinical Excellence (NICE), to develop 
a coherent programme of activity including guidance on clinical and cost-
                                                            
1 At the first phase of the HImP (1999-2002) only PCGs existed but now many PCGs have 
become PCTs.  
2 This report focuses on the second phase of HImPs for the period 2000-2003. Use of Economic Evidence in the Design of HImPs 
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effectiveness (NHS Executive, 1998).  Its’ role was to assess existing and new 
interventions for their clinical and cost-effectiveness and to provide patients, 
health professionals and the public with authoritative, robust and reliable 
guidance on current “best practice”.  Therefore its potential contribution to 
service delivery is explored in this report in relation to the HImP. 
 
Filtering down from the Government, intelligence systems have been set up to 
organise the evidence base, particularly at the national level through initiatives 
such as “Information for Health: An Information Strategy for the Modern NHS 
1998-2005” (Burns, 1998).  One of the purposes of this information strategy 
was to “ensure the availability of accurate information for managers and 
planners to support local Health Improvement Programmes”.  Public Health 
Observatories were launched in 2000 and were set up as “a resource for 
enquiry - searching for and compiling information and datasets on the nation's 
health and distilling from them the knowledge to guide its improvement” 
(http://www.pho.org.uk/).  It is anticipated that such information sources have 
contributed to the production of phase three HImPs (Hansell et al, 2000). 
 
3.  Review of the Literature 
 
Unsurprisingly, little evaluation of HImPs has been undertaken to date, as 
HImPs are still very much in their infancy.  However, some early assessments 
have been made.  The conclusion in the report “Improving HImPs: The early 
lessons”, which concentrated on the first phase of HImPs, was that HImPs have 
“proved to be more around the structures and processes of change, and less 
about outcomes of health improvement” (Carruthers et al, 1999).  First phase 
HImPs were produced over a period of three months so this result is to be 
expected, but over the long term HImPs need to deliver on health improvement 
if the initiative is to maintain its credibility. 
 
A similar project was undertaken by The King’s Fund in which an investigation 
of the lessons to be learnt from the first year of HImPs was undertaken (Arora 
et al, 1999).  A survey of a selection of London-based health authorities, local 
authorities and PCGs/Ts was conducted to find out about their perceptions of 
HImPs.  One of the main themes that emerged was that resources need to be 
directed towards appropriate activities and that measures to evaluate progress 
are needed.  The report highlighted the importance of setting targets based on 
evidence and it emphasised the role of well-researched performance indicators 
to link aspirations to practice. 
 
Another important point made by Arora et al was that the HImP involves 
changing responsibilities among the workforce involved in the HImP (Arora et 
al, 2000).  For instance, the PCGs/Ts are taking on board some commissioning 
of health services whereas this has traditionally been the reserve of the health 
authorities.  A consequence of this is that local authorities will be working quite 
closely with the PCGs/Ts, whereas to date they have worked more closely with 
health authorities.  Hudson makes the point that little research has been 
conducted into what effective inter-agency co-operation is or how it is best 
managed (Hudson, 1998).  If collaborative efforts are mandatory and set in a Use of Economic Evidence in the Design of HImPs  8 
top-down fashion, then those involved in HImPs might not need to recourse to 
the evidence directly.  On the other hand, if some elements of partnership are 
to be devolved to the local level, then presumably evidence to inform local 
decision making is important. 
 
Until very recently, with advances such as the Public Health Observatory, the 
research and information base at the local level has been less well developed 
than that of the national level.  However, additional information systems are 
needed to support PCGs/Ts in implementing better care for patients (Kilner et 
al, 1999).  Potentially organisations such as PCGs/Ts are able to identify 
patient groups and therefore are in a key position to realise the long-term goal 
of improving health, however defined (Hunter et al, 2000). 
 
4.  Methods 
 
4.1  Project design overview 
 
In order to assess the use of evidence (in particular, economic evidence) in the 
design of HImPs a three stage research project was undertaken.  First, a postal 
questionnaire was sent to each of the 102 Health Authorities within England in 
order to gain insight into HImP leaders’ thoughts and actions relating to the use 
of evidence in the design of HImPs
3.  A 67% response rate was achieved.   
Second, a convenience sample of 10 individuals, who indicated in the 
questionnaire that they would be willing to participate in a semi-structured 
telephone survey, were contacted.  The telephone interviews were used to 
obtain more detailed information on respondents’ thoughts on HImPs and the 
role of evidence, and also to explore themes emerging from preliminary 
analysis of the postal survey data.  Third, a random sample of 26 (25%) of the 
2000 - 2003 HImP documents were collected and a standard set of information 
was extracted
4 from each of them.  The aim of the last stage of research was to 
explore the contribution of evidence to the written documents and to see what 
evidence was cited within the text. 
 
Table 1:  Project design 
 
Evidence source  Sample size n (%) 
Responses from 102 health authorities in England  68 (67%) 
Interviews with HImP co-ordinators  10 (10%) 
HImP Reports (102 in total)  26 (25%) 
 
 
For the purposes of this study, two types of evidence were distinguished.  One 
type of evidence may be categorised as internal/experiential evidence, based 
on professional opinion and tacit knowledge.  The second type of evidence may 
be termed external/empirical evidence, that is evidence based on research from 
primary and/or secondary studies, such as guidelines or published studies 
(Brechin et al, 2000).  By defining evidence in this way, the aim was to show the 
                                                            
3 See appendix 9.1 for the postal survey. 
4 See appendix 9.2. Use of Economic Evidence in the Design of HImPs 
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variety of evidence available.  However, in practice it is recognised that the 
distinction between internal and external evidence might be blurred since it is 
likely, for example, that clinical decision making be informed by both the internal 
and external evidence base. 
 
4.2  Postal survey on the role of evidence in the design of HImPs 
 
A 12 page postal questionnaire was designed containing a total of 23 questions 
with 17 closed-ended questions and six open-ended questions (see appendix 
9.1).  As part of the research into the role of evidence in the design of HImPs, 
three main issues were investigated.  First, HImP leaders views on the rationale 
behind the HImP were explored; second, any attempt to include evidence in 
practice were investigated; third respondent’s expectations about the future 
direction of HImPs were elicited.  Initially the questionnaire was piloted on four 
individuals working within different health authorities and four researchers 
within Centre for Health Economics. 
 
The questionnaire was sent to the HImP leader of every health authority, as 
identified through Binley’s database (Binleys, 2000).  In the introduction to the 
questionnaire HImP leaders were encouraged to consult any colleagues who 
were closely involved in the production of the HImP.  A fortnight after the 
questionnaire was sent out a second, duplicate, questionnaire was sent to 
those health authorities from whom no response had been received. 
 
In the part of the questionnaire dealing in more detail with the acquisition and 
use of evidence, HImP leads were asked to make a choice between providing 
feedback on either the CHD or the cancer programme within their HImP.  CHD 
and cancer programmes were chosen because they were nationally mandated 
targets for health improvements (NHS Executive, 1999).  Also, there is a 
considerable body of medical and economic evidence in both disease areas so 
we hoped to find positive results for the use of evidence. 
 
4.3  Telephone interviews of HImP leaders 
 
To explore the role of evidence in the design of HImPs more comprehensively, 
we conducted semi-structured telephone interviews of 10 HImP leaders.  The 
HImP leaders chosen for interview were selected for two main reasons: either 
(i) because they raised interesting issues in their responses to the open-ended 
questions in the postal questionnaire or (ii) because their responses raised 
issues about the use of economic evidence that we wished to explore.  The 
telephone interviews lasted approximately half an hour each and every 
interviewee was asked about their job background, their training background 
and then about the rationale behind some of their responses.  One of the 
researchers involved in this project took notes throughout the series of 
interviews and these were transcribed for review. 
 Use of Economic Evidence in the Design of HImPs  10 
4.4  Review of HImP documents 
 
Health authorities are obliged to produce a yearly HImP report that covers a 
three year period and which is available within the public domain.  A random 
sample of 26 (25%) HImPs were obtained, either by downloading them from the 
website (http://www.oliveweb.clara.net/n-fset-ha.htm), or by calling the health 
authorities direct.  Thirteen HImPs were reviewed for evidence on cancer 
interventions and 13 HImPs were reviewed for evidence on Coronary Heart 
Disease (CHD). 
 
To extract a standard set of information from each of the 26 HImPs, a pro-
forma was constructed (appendix 9.2).  This pro-forma contained eight 
questions, including what disease areas covered in the HImP, references to any 
specific government guidance, reference to the external evidence, use of 
economic terms and notification of any quantifiable targets set.  Two 
researchers independently reviewed six of the HImPs and their results were 
compared to ensure consistent review.  Following this, one of the researchers 








Of the 102 postal questionnaires sent out, 68 were returned giving a response 
rate of 67%.  The response rate was relatively uniform by geographical area 
and the response rate was similar to that achieved in a number of other postal 
questionnaires sent to health care decision-makers (Gosden et al 2000; Mason 
et al 1999).  Whilst the questionnaires were sent directly to HImP leaders, 
anyone who had participated in the design of the HImP was encouraged to 
participate in its completion.  The majority of respondents worked in Public 
Health Departments.  Other respondents worked in a variety of departments 
including business management, health promotion, strategy, planning and/or 
corporate affairs departments.  Individuals working at different levels of 
management answered the questionnaire, including Directors of Public Health, 
HImP leads and Co-ordinators and Public Health Specialists, among others.  
Most respondents were medically trained and the remaining respondents were 
trained in a range of other disciplines including statistics, operational research, 
management studies, science and accountancy.  Four respondents explicitly 
mentioned that they had some training in economics/health economics.   
Questionnaire results are provided below. 
 
5.1.2  The objectives of HImPs 
 
Potentially there are a number of objectives of HImPs.  The questionnaire gave 
respondents a number of possible objectives to rank in importance.  The list 
was derived mainly from the aims stated in the White Paper establishing 
HImPs. Use of Economic Evidence in the Design of HImPs 
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The most obvious objective of the HImP is to improve health.  However, it was 
interesting to assess what respondents thought the rationale behind the HImP 
was in practice.  All respondents thought health improvement was either ‘very 
important’ (94%) or ‘quite important’ (6%).  Considerable importance was also 
attached to the HImP as a means to reduce inequalities in health and to 
encourage partnership in the provision of care, with 87% and 82% of 
respondents saying these two objectives were ‘very important’. 
 
Besides the objectives specified in the questionnaire, a number of respondents 
made additional suggestions and most of these were process-focused 
objectives.  For instance, respondents mentioned partnership in the definition of 
priorities and target setting, initiating Primary Care Trusts (PCTs) and making 
them responsible for health improvement, raising awareness of the contribution 
of different organisations to the health agenda, and integrating financial 
planning with health policy objectives. 
 
Based on the results summarised in Table 2 below, it can be seen that all the 
objectives stated in the questionnaire were considered to be ‘very important’ by 
over a quarter (27%) of the sample of respondents and one possible implication 
of this is that a number of the objectives may compete for prime importance. 
 
Table  2:  In your view, within your HImP what are the objectives of 
HImPs? How important are the following? 
 










To improve health  64 (94%)  4 (6%)  -  -  - 
To reduce health inequality  59 (87%)  8 (12%)  1 (2%)  -  - 
To encourage partnership in 
the provision of care 
56 (82%)  11 (16%)  1 (2%)  -  - 
To identify local priorities in 
health care provision 
47 (69%)  18 (27%)  3 (4%)  -  - 
To provide a performance 
management framework 
26 (38%)  32 (47%)  8 (12%)  2 (3%)  - 
To focus on efficient 
provision of care 
20 (29%)  39 (57%)  8 (12%)  1 (2%)  - 
To organise and co-ordinate 
health care provision 
18 (27%)  38 (56%)  8 (12%)  3 (4%)  1 (2%) 
Other  14  (21%)  - -  - - 
 
NB – some % add up to more than 100% due to rounding 
 
5.1.3  The prime objective of the authority’s HImPs 
 
Out of the list of objectives above, respondents were asked to indicate what 
they believed to be the prime objective of the HImP.  Unsurprisingly, the 
majority of respondents (47%) argued that the prime objective of the HImP was 
to improve health (see Table 3).  However, substantial numbers of respondents 
thought that the reduction of health inequality (16%), or the use of the HImP as 
a means to identify local priorities in health care provision (15%), had the 
greatest importance. Use of Economic Evidence in the Design of HImPs  12 
Table 3:  In your view what was the prime objective of the HImP that 
you were involved in? 
 
Objectives of the HImP  Frequency  Percent 
To improve health  32 47% 
To reduce health inequality  11 16% 
To identify local priorities in health care provision  10 15% 
To encourage partnership in the provision of care  7 10% 
To provide a performance management framework  3 4% 
To organise and co-ordinate health care provision  1 2% 
To focus on efficient provision of care  - - 
Missing data  4 6% 
 
One respondent commented that the HImP is the only policy for which the 
combined objectives of improving health, reducing health inequality and 
identifying local priorities in health care provision are prime.  In practice, these 
objectives might sometimes diverge, in which case trade-offs may need to be 
made between them. 
 
One respondent suggested that partnership is important within HImPs and 
therefore local government and multi-district bodies need to make decisions 
that are concordant with one another.  A few other respondents mentioned a 
more fundamental point; namely, the need to define what health is and 
whether, for example, the HImP approach was based on a broad socio-
economic model of health or a narrower, medically driven model.  The two 
types of approaches could result in entirely different strategies being adopted. 
 
The fact that HImPs were considered to have multiple objectives, with 
improving health the prime objective, is hardly surprising.  Perhaps more 
surprising is the low ranking given to the efficient provision of health care, given 
the emphasis being placed on this by the Department of Health. 
 
5.1.4  Staff involvement in the production of the HImP 
 
Respondents were asked which groups of people were consulted in the 
production of their HImP and the results show that the scope of the consultation 
exercise was very broad.  Besides consulting other health authority staff, all 
respondents said that the NHS Trusts and the PCG/Ts were consulted.  For 
those health authorities that were a Health Action Zone (HAZ), board members 
from the HAZ were consulted in relation to the HImP.  The following 
percentages of respondents said that these local authority departments were 
involved in the production of their HImP: social services (99%), housing (88%), 
education (88%) and transport (71%).  Within the local authority, other groups 
that provided input into the production of the HImP included health policy 
managers, the local medical committee, economic development units, the 
police force, the fire service, local schools and sports centres. 
 
In addition to local authority involvement, 93% of respondents said that the 
community health council was consulted.  Also, 88% consulted voluntary bodies 
and 71% consulted the local population.  Other organisations and groups of Use of Economic Evidence in the Design of HImPs 
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people involved in the consultation process included: the independent sector 
(e.g. nursing homes, local businesses), charitable concerns, race action 
groups, universities, MPs and carers.  One respondent mentioned that, for the 
first phase of the HImP, numerous agencies were consulted but that now they 
mainly focused on consultations with the local authorities and the PCG/Ts.  It is 
therefore likely that the consultation process will change over time. 
 
5.1.5  The overall quality of the evidence base of the HImP 
 
As part of the questionnaire HImP leaders were asked if, in general, the 
evidence base for the HImP met their expectations.  Most respondents said that 
they were ‘quite satisfied’ about the evidence base of the HImP but a sizeable 
proportion (29%) said that they were ‘not very satisfied’ with the evidence base.  
Overall the reaction of respondents was quite mixed and so it seems there is 
much work to be done to provide the evidence that HImP leaders would like. 
 
Table 4:  Overall, would you say the internal/external evidence base of 
the 2000-2003 HImP met your expectations? 
 
 Frequency  Percent 
Completely satisfied  5 7% 
Quite satisfied  39 57% 
Not very satisfied  20 29% 
Not at all satisfied  1 2% 
Missing data  3 4% 
 
The respondents who said they were ‘quite satisfied’ rather than ‘completely 
satisfied’ argued that there is always room for improvement in the evidence 
base, so this answer could reflect high expectations on the part of some 
respondents.  Reasons respondents gave for stating that they were ‘completely 
satisfied’ were that the HImP is a good balance of widely accepted external 
evidence combined with the experience of local people and organisations 
(internal evidence).  Such respondents added that they liked the partnership 
idea behind the HImP and said that the inter-agency consultation process 
required to design the HImP in itself encouraged collaboration.  One 
respondent mentioned that because, in their health authority, they had met the 
national targets, their HImP was a success.  Again this point shows that the 
answer to this question very much depends on HImP leaders expectations. 
 
A number of themes emerged from those respondents who were ‘quite 
satisfied’ with the use of evidence in their HImP.  An over-riding message was 
that the HImP process and health needs assessment were in early stages of 
development and that there was a learning curve to be climbed in implementing 
central priorities whilst trying to match local needs.  Generally, respondents 
found that priorities issued as “must dos” from central government were well 
researched and based on empirical, external evidence.  Or at least, this is what 
respondents stated they had assumed.  While central government directives 
were considered to have a positive impact in most cases, one respondent 
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local priorities further down the list, so there needs to be flexibility within the 
approach to ensure an appropriate balance.  In terms of setting priorities at the 
local level, the evidence tended to be based on local good ideas and 
discussions. 
 
In theory respondents saw the use of evidence as a good thing and many 
believed that evidence was being translated into practice.  However, a few 
respondents pointed out that the decision-making process is multi-faceted and 
so factors such as the political acceptability of the programme and professional 
reasoning make important contributions within the decision making framework 
too.  Therefore, while external evidence may be available it might not always be 
used.  However, some respondents stated that they thought the HImP was an 
intrinsically good idea for enhancing the use of research.  One respondent said 
that through the HImP “a comprehensive network had been set up to develop 
an intelligence source that was ‘close’ to priority groups”. 
 
One commentator argued that evidence was sometimes used to support 
current arrangements of health and social care provision even if there were no 
quality indicators of the research.  A few respondents did say that they judged 
the quality of evidence and found it to be variable.  Therefore, their general 
satisfaction did sometimes mask dissatisfaction over particular areas of the 
evidence base.  One respondent argued that there is a strong clinical base of 
evidence, as compared with the evidence base on “broad picture” issues such 
as social inclusion and health (in)equalities.  Another added that there was 
“Quite a bit of evidence to support investment/disinvestment of clinical 
interventions (and) not enough around effective implementation strategies and 
effective organisation of care”. 
 
5.1.6  The role of economic evidence in the design of HImPs 
 
The use of economic evidence in the design of the HImP was of particular 
interest in this project.  Overall the response to this question was positive, with 
the majority of respondents (58%) saying that they believed that economic 
evidence should influence the design of HImPs ‘quite a bit’ and with 24% of 
respondents saying ‘yes, very much so’. 
 
Table 5:  Do you think that economic evidence (relating to issues such 
as costs or cost-effectiveness) should influence the design of 
HImPs? 
 
 Frequency  Percent 
Yes, very much so  16 24% 
Yes, quite a bit  40 58% 
Only marginally  10 15% 
No  - - 
Missing data  2 3% 
 
Respondents who were fully in favour of the use of economic evidence in the 
design of HImPs were clear that economics can be used as a decision aid for 
choosing cost-effective interventions.  A number of respondents stated that Use of Economic Evidence in the Design of HImPs 
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economics is useful for assessing how to obtain the most health gain from the 
limited resources available.  However, the concern was expressed that where 
resources were limited, the issue of explicit rationing was problematic.  Some 
comments made about the use of economic evidence within the HImP are 
provided in the boxes below. 
 
“The HImP is the basis for key investment decisions, for allocating 
scarce resources against competing demands both effectively and cost-
effectively.” 
 
“The more cost-effective use of resources achieved will result in greater 
potential to meet health needs.” 
 
“Plans should be both feasible in cost terms and lead to effective 
services (both clinically and cost-effective).  However, I think we still 
have a long way to go before we can demonstrate clearly the cost 
implications of one services development on other services.  For 
instance it is often asserted that the development of preventative health 
services will achieve cost savings elsewhere, but I am aware of very little 




For the 15% of respondents who were only ‘marginally convinced’ of the 
contribution of economic evidence to the design of HImPs, the concerns raised 
were primarily practical ones.  For instance, the absence of local economic 
evidence was mentioned.  In principle, most respondents thought that 
economic evidence was a good thing.  However, the most immediate goal, at 
this early stage of HImP development, was to set up the HImPs and to ensure 
effective joint working.  The suggestion was that economic evidence will have a 
stronger role to play in the future.  A few of the respondents who expressed 
some reservations about the use of economic evidence did not appear to have 
a full understanding of economics.  For instance they equated economics with 
finance or they defined economics in terms of costs alone.  A number of 
respondents said that besides cost-effectiveness arguments, other outcomes of 
provision, such as social equity and political acceptability of programmes, were 
also important. 
 
Some HImP leaders mentioned that there was a lack of clear and easily 
implementable recommendations from economic studies.  Also it was said that 
some aspects of the economic evidence were limited.  For instance, little 
information was available on the costs and benefits of the multi-agency 
partnerships that HImPs build upon.  One HImP leader argued that the impact 
of historical precedent was a stronger influence on the status quo than the 
evidence supporting the revision of existing organisational arrangements.  It is 
likely that any type of evidence will take some time to incorporate within the 
HImP, particularly in the light of a culture change from healthcare to a more 
integrated approach to health and social care provision. Use of Economic Evidence in the Design of HImPs  16 
Table 6:  For the HImP that you were involved in, how important were 
the following sources of external empirical evidence in deciding what 
Coronary Heart Disease or Cancer services to provide? 
 






















27 (40%)  19 (28%)  10 (15%)  -  5 (7%)  7 (10%) 
NICE guidance  25 (37%)  19 (28%)  13 (19%)  1 (2%)  1 (2%)  3 (4%) 
Clinical 
guidelines e.g. 
choice of ACE 










Royal College of 
Surgeons 




























-  6 (9%)  15 (22%)  8 (12%)  37 
(54%) 
2 (3%) 
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5.1.7 The use of external evidence sources in the Cancer or CHD 
sections of the HimP 
 
Respondents were asked what sources they had used to obtain external 
evidence.  The large majority of respondents (78%) considered the National 
Service Framework guidelines to be ‘very important’.  Government publications, 
National Institute of Clinical Excellence (NICE) guidance and clinical guidelines 
were also reported to be ‘very important’ by 40%, 37% and 35% of respondents 
respectively.  Guidance from professional associations, secondary sources of 
information, published cost-effectiveness analyses and general published 
literature were considered to be ‘very important’ by 16%, 15%, 15% and 13% of 
respondents respectively.  Work directly commissioned to academic 
researchers was considered very important for 7% of respondents and 
management consultants were not considered to be a very important source of 
empirical evidence by any of the respondents.  Other sources of evidence 
suggested by respondents included updates from the National Heart Team, 
regional groups such as an oncology forum, Annual Public Health reports and 
the Cochrane Library and Medline. 
 
5.1.8  Importance of different internal evidence sources 
 
As seen in Table 7 below, 93% of respondents thought that clinical opinion was 
either ‘very important’ or ‘quite important’ and 78% of respondents thought that 
the opinion of health care managers was ‘very important’ in deciding how to 
provide services to meet the priorities identified.  Public opinion and patient 
advocacy groups were said to be ‘very important’ by only 12% and 9% of 
respondents respectively.  However they were thought to be ‘quite important’ by 
44% and 41% of respondents respectively.  One respondent said that the NSF 
priorities were the key sources of evidence and, since they left very little scope 
for choice, that this particular question was difficult to answer. 
 
Table 7:  For the HImP programme that you have chosen to focus on, 
how important were the following sources of internal 
evidence in deciding what Coronary Heart Disease / Cancer 
services to provide to meet the priorities identified? 
 










Clinical opinion  31 (46%)  32 (47%)  3 (4%)  1 (2%)  1 (2%) 
Health care managers 
opinion 
17 (25%)  36 (53%)  12 (18%)  1 (2%)  2 (3%) 
Public opinion  8 (12%)  30 (44%)  23 (34%)  5 (7%)  2 (3%) 
Academic researchers 
opinion 
6 (9%)  18 (27%)  26 (38%)  14 (21%)  4 (6%) 
Patient advocacy 
groups 
6 (9%)  28 (41%)  26 (38%)  5 (7%)  3 (4%) 
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5.1.9  Balance between internal and external evidence 
 
Table 8:  Would you say that the balance of evidence to decide upon 
interventions was mainly internal or external? 
 
Type of evidence  Frequency  Percent 
All internal evidence  - - 
More internal evidence than external evidence  15 22% 
More external evidence than internal evidence  45 66% 
All external evidence  3 4% 
Missing data  5 7% 
 
The responses to this question clearly illustrate there is a balance between the 
use of internal and external evidence, with more emphasis on the latter.  This is 
consistent with the emphasis placed on NSFs and government publications in 
5.1.7. 
 
5.1.10 Information collectors for the HImP 
 
Table 9:  Who was given the job of finding information? 
 
Information collectors  Frequency  Percent 
Clinician/s  39 57% 
HImP leader  36 53% 
Information officer  34 50% 
Researcher/s  19 28% 
Administration staff  15 22% 
 
 
Besides clinicians, a large number of questionnaire respondents (i.e. the HImP 
leaders), (53%) said that they had the job of finding information for the HImP.  
This suggests that these individuals were therefore particularly well placed to 
answer our questionnaire.  Half of the respondents said that an information 
officer was also responsible for information collection and this is encouraging, 
as presumably they would have good literature search skills. 
 
A few other individuals or groups of people contributing to the information 
collection effort were mentioned by the respondents.  These included Public 
Health Department colleagues, managers of specific service areas, staff from 
all health authority directorates and multi-agency groups. 
 
5.1.11 Resources for the development of the HImP 
 
Forty-six percent of respondents thought that the number of epidemiologists 
available to collect information was ‘satisfactory’, 44% thought that the level of 
clinical expert resources available were ‘satisfactory’ and 37% of respondents 
thought that the number of information officers available was ‘satisfactory’.  In 
contrast, 47% of respondents thought that there were ‘insufficient’ health 
economics resources and 37% of respondents thought that there were 
‘insufficient’ financial resources available. Use of Economic Evidence in the Design of HImPs 
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Table  10:  Did you find there was “satisfactory”, “limited” or 
“insufficient” supply of resources for the design of HImPs for 
the following resource examples? 
 
Resource type  Satisfactory  Limited  Insufficient  Missing data 
Epidemiologist  31 (46%)  21 (31%)  11 (16%)  5 (7%) 
Clinical expert  30 (44%)  24 (35%)  8 (12%)  6 (8%) 
Information officer  25 (37%)  24 (35%)  14 (21%)  5 (7%) 
Financial resources  12 (18%)  26 (38%)  25 (37%)  5 (7%) 
Health services researchers  11 (16%)  28 (41%)  19 (28%)  10 (15%) 
Health economist  2 (3%)  26 (38%)  32 (47%)  8 (12%) 
 
5.1.12 Use of different types of economic evidence 
 
Twenty-four percent of respondents said that advice from such bodies as NICE 
was ‘very useful’ in the production of the HImP.  The majority of respondents 
(52%) neither used information gathered from conferences where economic 
evidence was being discussed, or used evidence collected during discussions 
or advice from economists (62%). 
 
Table  11:  Did you find the following types of economic evidence 
useful? 
 














Discussion and advice 
from economists 





published as reports or in 
journals 




effectiveness in health 




30 (44%)  17 (25%)  2 (3%)  6 (9%)  3 (4%) 
Advice from such bodies 
as NICE  
16 
(24%) 
23 (34%)  15 (22%)  2 (3%)  9 (13%)  3 (4%) 
Conferences where 
economic evidence is 
discussed 




Other types of economic evidence that respondents found useful included 
some population-based models developed by the London School of Hygiene 
and Tropical Medicine, local sensitivity analyses on service models, and the 
results of Programme Budgeting / Marginal Analysis (PBMA) exercises. 
 
5.1.13 Use of different methods for collecting evidence 
 
More respondents (35%) made ‘considerable use’ of literature searches than 
any other method of collecting evidence.  Overall, questionnaires were the least 
popular method used for collecting evidence, with 40% of respondents saying 
they did not use this technique. Use of Economic Evidence in the Design of HImPs  20 
Table  12:  What was the method used for collecting evidence in the 
design of HImPs? 
 
  Considerable use  Some use  Little use  Not used  Missing data 
Literature 
searches 
24 (35%)  27 (40%)  4 (6%)  9 (13%)  4 (6%) 
Internet  18 (27%)  27 (40%)  7 (10%)  12 (18%)  4 (6%) 
Focus groups  13 (19%)  23 (34%)  10 (15%)  17 (25%)  5 (7%) 
Interviews  11 (16%)  18 (27%)  16 (24%)  17 (25%)  6 (9%) 
Questionnaires  3 (4%)  14 (21%)  18 (27%)  27 (40%)  6 (9%) 
 
A number of respondents said that much of the evidence was collected at the 
DH and then disseminated to the NHS.  In addition to the collection methods 
stated above, local networks, consultation groups, stakeholder meetings and 
local authority meetings were also used for gathering evidence.  A few HImP 
leaders have produced pro-formas for service providers to complete when 
bidding for contracts, and typically these ask for evidence in support of the 
service developments being proposed. 
 
5.1.14 Use of economic evaluation studies 
 
Forty-one percent of respondents (n=28) stated that they were aware of 
economic evaluations for CHD or cancer interventions.  More respondents 
knew of CHD economic evaluations than cancer ones.  Of the 47 HImP leaders 
who chose to focus on CHD, 47% said that they were aware of economic 
evaluations on interventions associated with CHD.  Eighteen respondents 
chose to focus on the cancer HImP and, of these, 33% said that they were 
aware of economic evaluations on interventions associated with cancer. 
 
Table  13:  Are you aware of any economic evaluations (e.g. cost-
effectiveness studies) on either Coronary Heart Disease or 
Cancer that were used in the production of the HImP that you 
have chosen to focus on? 
 
Cancer/CHD  Percent 
Cancer  33% 
CHD  47% 
Missing data  2% 
 
If respondents answered in the affirmative, they were asked to provide 
references to verify their answer.  Scientific journals that were stated to provide 
useful sources of economic evidence included British Medical Journal (BMJ), 
Effective Health Care Bulletins, HEART, Bandolier, PharmacoEconomics, the 
Lancet, Thorax and prescribing journals.  Actual studies mentioned included 
costs and benefits of cholesterol lowering strategies, such as the use of statins 
in CHD. 
 
Examples of studies undertaken by respondents themselves included those on 
equity of access to Coronary Artery Bypass Grafting (CABGs) and use of lipid 
lowering agents.  Two respondents said that they had commissioned research, Use of Economic Evidence in the Design of HImPs 
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including a study on the cost-effectiveness of statins using the World Bank 
Disability-Adjusted Life Year (DALY) approach. 
 
References made to reports and working papers included Clinical Outcomes 
Guidance (COG guidance, 1998), DEC reports, Health Technology 
Assessments (HTA) (e.g. 1998, Vol. 2, No. 10), NHS Centre for Reviews and 
Dissemination Effective Health Care Bulletin (e.g. Feb 1998, Vol. 4, No.1), 
National Institute of Clinical Excellence (NICE) reports, local drug information 
services and the white paper, “Smoking Kills: A White Paper on Tobacco” (NHS 
Executive, 1998).  Some respondents mentioned specific reports based on 
work in their own local authorities, for example a local report on Taxanes for 
Ovarian Cancer and a city-wide initiative for reducing cardiovascular disease. 
 
Four respondents named databases that had been searched for the evidence 
and these included the Cochrane library, Medline, OHE HEED and some 
websites such as that of NICE (http://www.nice.org.uk/nice-web). 
 
5.1.15 Deciding on priorities for action 
 
As mentioned earlier, in order to investigate how HImP leaders decided upon 
priorities for action within their HImPs, we chose two disease areas, CHD and 
cancer.  There is an NSF available for CHD and a similar document on cancer 
services (the Calman-Hine report).  Within our questionnaire 27% of 
respondents chose to report on their cancer HImP and 69% chose to focus on 
their CHD HImP.  The remainder either provided information on both or failed to 
respond to the question.  The examples of cancer and CHD service priorities 
were chosen based on national targets. 
 
For those respondents who chose to focus on cancer, 24% of respondents 
included increasing management of cancer care by specialist multidisciplinary 
teams as a priority.  Just over a quarter of respondents (28%) indicated that 
their health authority was beginning, or intensifying smoking cessation and 
discouragement efforts.  Fifteen percent of respondents said that within their 
HImP a priority was cancer surgery to surgeons who demonstrate good results 
and 18% of respondents said that a priority was to establish dedicated 
diagnostic/assessment services for gynaecological cancer with cancer units. 
 
Table 14:  Examples of cancer service priorities 
 
Cancer Frequency  Percent 
Increasing management of cancer care by specialist 
multidisciplinary teams 
16 24% 
Beginning (or intensifying smoking cessation and 
discouragement efforts 
19 28% 
Concentrating cancer surgery to surgeons who 
demonstrate good results 
10 15% 
Establishment of dedicated diagnostic/assessment 
services for gynaecological cancer within cancer units 
12 18% 
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As shown in Table 15, of those respondents who chose to focus on CHD, 49% 
of respondents said that increasing efforts to treat those with blood pressure 
were being made within their HImP; 72% of respondents said that they were 
beginning (or intensifying) smoking cessation and discouragement efforts; 54% 
promoting healthy eating lifestyle; and 41% said that they were undertaking 
efforts to reduce obesity in their health authority. 
 
Table 15:  Examples of CHD service priorities 
 
CHD Frequency  Percent 
Increasing efforts to treat those (especially the elderly) 
with high blood pressure 
33  49% 
Beginning (or intensifying) smoking cessation and 
discouragement efforts 
49  72% 
Promoting healthy eating lifestyle  37  54% 
Efforts to reduce obesity  28  41% 
 
5.1.16 Specific sources of evidence in deciding on priorities in cancer or 
CHD 
 
HImP leaders were asked if there were any specific sources of evidence that 
they used to decide on priorities for CHD/cancer.  At the national level, the NSF 
was frequently quoted as a source to decide on priorities.  Regional and 
national policies and directives were generally expressed to be useful.  A 
number of reports provided from central Government were also cited, including 
COG guidance, cancer accreditation services and the Calman-Hine report.  The 
Acheson report, which supplies information on both cancer and CHD risk 
factors, and smoking cessation reports were also cited.  Other evidence 
mentioned as useful included Cochrane Reviews and other published 
systematic reviews.  Local sources of evidence included recommendations of 
regional cancer working groups, local information such as that on 
revascularisation rates, and public health reports.  One respondent stated that 
they had used information on the relative cost-effectiveness/utility of various 
health care interventions. 
 
5.1.17 Main barriers to using evidence in the design of HImPs 
 
In collecting information on the use of evidence it is important to explore 
perceived barriers to the use of evidence.  Between 25% and 50% of the 
respondents stated that there was some truth in the following statements: that 
relevant evidence is not available; that the evidence is available but makes 
some untenable assumptions and therefore is not easy to apply in practice; that 
the evidence is available but is either not accessible nor understandable; that to 
some extent evidence is available but no consensus could be reached on 
whether to use it or not; that there was not enough time to look for evidence; 
and that there was too much information available. 
 
Comments added by respondents included the belief that economic evidence 
does not take full account of the difficulties involved in the reconfiguration of Use of Economic Evidence in the Design of HImPs 
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complex services and that politics and public relations were important elements 
driving decisions. 
 
Table  16:  What do you think the main barriers to using evidence in 
HImP design are? 
 




Not true  Missing 
data 
There is not enough time to 
look for evidence. 
13 (19%)  20 (29%)  18 (27%)  9 (13%)  8 (12%) 
Relevant evidence is not 
available 
6 (9%)  21 (31%)  18 (27%)  16 (24%)  7 (10%) 
Too much information is 
available 
5 (7%)  9 (13%)  23 (34%)  19 (28%)  12 (18%) 
Evidence is available but 
consensus on whether to 
use it  could not be reached 
5 (7%) 
 
21 (31%)  13 (19%)  19 (28%)  10 (15%) 
Evidence is available but is 
not understandable / 
accessible  
1 (2%)  14 (21%)  21 (31%)  19 (28%)  13 (19%) 
Evidence is available but it 
makes untenable 
assumptions 
-  14 (21%)  25 (37%)  16 (24%)  13 (19%) 
 
A few barriers were thought to constrain the use of the evidence base.  For 
instance, the speed at which the production of the HImP had to take place 
sometimes prevented thorough research being undertaken.  Also there was not 
always the staff or the expertise needed to explore the research literature on 
different options for care.  One respondent reported that the lack of resources 
was not the only problem.  Rather, substantial routine data were collected but 
could not be utilised fully as they were not linked to addresses and therefore 
could not be used to generate a picture of the health of the local community.  
Another respondent stated that they would like more evidence that helped them 
link available resources to health priorities and to have the tools available to link 
actions taken locally with improvements in the health status of the local 
population. 
 
5.1.18  Suggestions for improving the evidence base when choosing 
between different interventions for either CHD or cancer 
 
Besides the use of evidence mentioned in Table 17 below, respondents made 
several other suggestions for improving the evidence base.  These were (i) 
results from audits, (ii) patient experience, (iii) burden of disease and modelling 
the impact, including resource implications, (iv) systematic reviews and (v) 
timely access to local authority and mortality data. 
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Table 17:  What kind of evidence do you think would help to improve the 
decision making process when faced with a choice between 
















37 (54%)  19 (28%)  4 (6%)  -  8 (12%) 




25 (37%)  29 (43%)  9 (13%)  -  5 (7%) 




8 (12%)  33 (49%)  21 (31%)  -  6 (8%) 
Management 
opinion 
4 (6%)  30 (44%)  25 (37%)  1 (2%)  8 (12%) 
 
5.1.19 Suggestions for improving the evidence base overall 
 
Respondents were given the chance to suggest any improvements to the type 
of information available to improve the HImP.  Information provided through the 
NSFs was welcomed and a few respondents mentioned that they would like 
more information produced by the government.  One of the chief concerns was 
that there is inadequate information available at the systems level; that is, 
across the multiple health and social care providers.  Respondents mentioned 
the lack of studies on the comparative cost-effectiveness of different models of 
care across the whole health sector.  Some respondents said that cost-
effectiveness information was available in some cases, but that economic 
evidence relating to the implementation of services was rarely available, 
particularly information on the impact of organisation of care across the multiple 
agencies involved in provision. 
 
Two other types of information relating to organisational aspects of service 
provision were called for; namely, disinvestment criteria across all agencies and 
cost information on work-force planning.  A number of HImP leaders suggested 
that information linking national priorities for interventions to the local level, 
through local needs assessment for instance, was needed. 
 
At the local level, more and better quality financial and epidemiological 
information was called for.  The local action plans for a number of HImPs were 
linked to PCGs/Ts and therefore there was a call for more primary care based 
research.  Specific types of information which respondents would like to obtain 
more of included Quality Adjusted Life Year (QALY) and Disability Adjusted Life 
Year (DALY) information associated with interventions. 
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A number of respondents were concerned that within studies inadequate 
consideration was given to the effect of interventions on the distribution of 
provision.  For instance, they felt that while interventions may be cost-effective 
they wanted information on the equity issues associated with using such 
interventions.  There was a call for more external evidence on inequalities and 
how to judge priorities in relation to inequality.  Also, information on target 
setting and the use of indicators to reduce health inequality and the resource 
requirements was requested.  Other types of external evidence, for which more 
information was requested, included health promotion and community 
development.  One respondent said that more attention needs to be paid to 
valuing the benefits of programmes over the long term.  It was suggested that 
the benefits of many prevention activities would only be felt over a long time 
period.  Concentrating on activities that impact on health in the short term could 
lead back to a medical-based model of provision rather than a socio-economic 
one. 
 
Focusing on the delivery of HImPs, it was mentioned that staff commitment to 
the process was the priority and once that was achieved there would be 
improved use of the evidence.  Additionally, HImP leaders wanted more 
information on how to implement programmes in a cost-effective manner.  For 
instance, the evidence for some healthy lifestyle initiatives are well recognised, 
such as smoking cessation and increased exercise.  However, it was reported 
that no analyses exist concerning how best to implement such programmes. 
 
In general, concise, summarised information is needed as HImP leaders said 
that they were too busy making decisions to explore all the evidence.  Also, 
some individuals involved in producing the HImP do not have a background in 
medicine or science and therefore might have difficulty in appraising some 
types of evidence. 
 
5.1.20 The role of economic evidence in the future design of HImPs 
 
Respondents were asked about the contribution that they think that economic 
evaluation will make in the future design of HImPs.  On balance, most 
respondents (59%) were optimistic about the use of such evidence while 19% 
of respondents thought it would play a limited, minimal, or even negligible role 
in the HImP design.  Twenty-two percent of respondents either did not answer 
or said that they did not know if economic evidence would be part of the future 
evidence base of HImPs.  The respondents who were confident about the role 
that economic evaluation might play in the future design of HImPs, were clear 
about the strengths of economic evaluation, as summarised in the quote below. 
 
Economic evaluation should play a greater role so that we can be open 
and explicit about the choices that have to be made within limited 
resource envelopes. 
 
A suggestion made by a few respondents was to increase the use of economic 
evidence by improving the link between this information and targeted central 
funding.  Service and Financial Frameworks (SaFFs) were thought to be a good Use of Economic Evidence in the Design of HImPs  26 
budgetary tool to link HImP objectives to practice.  Respondents were keen to 
add that an appropriate supply of labour is needed to implement the 
recommendations in practice. 
 
Reasons given for reservations about the role of economic evidence in the 
future design of HImPs were mainly related to practical considerations, such as 
data limitations and the fact that HImPs have not long been established.   
Limited resources, including human resources and funding constraints, were 
given as reasons why economic evidence might not be utilised as much as it 
could be.  No concerns were voiced about economic evaluation methodology 
itself. 
 
A few HImP leaders mentioned that clinicians and politicians put the emphasis 
on health rather than money, and therefore felt that there was some resistance 
to cost-effectiveness information.  Concerns were voiced about the political 
acceptability of some programmes and the resources required to undertake 
appropriate cost-effectiveness research.  However, many respondents 
recognised that there was a difference between being cost-effective and merely 
cost cutting. 
 
In interpreting the responses to the questions about the usefulness of economic 
evidence (here and in Table 11), it should be recognised that respondents 
might be overly positive, knowing that health economists were conducting the 
survey.  However, many of the comments about the usefulness, or lack of use 
of economic evidence, were fairly forthright, which suggests that respondents 
were not overly inhibited by the researchers’ affiliation. 
 
5.1.21 Additional comments 
 
At the end of the questionnaire a section was left blank so that respondents 
could add any further comments if they wished.  A few respondents felt that 
there was more scope for evidence in disease areas other than cancer or CHD, 
as much evidence was already available for these two diseases.  In the other 
sections of the HImP, such as children and young people, it was argued that 
there was less research evidence available, that national targets were less 
directive, and therefore potentially there was more scope to gather information 
locally. 
 
Another point made was that the HImP is a summary document pooling many 
separate plans.  Therefore, there may be no evidence incorporated within them 
explicitly, although implicitly guidance and Government information such as the 
NSFs are based on research evidence.  One respondent said that targeted 
evidence-based central funding would be useful and this sentiment was 
expressed by many other HImP leaders throughout the questionnaire.  As one 
HImP leader stated, “HImPs are increasingly structured in line with NSFs and 
the directives from the new task forces.  As long as the ‘must dos’ from the 
centre match with good evidence and cost-effectiveness, then this speeds up 
the process of putting evidence into practice.” 
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The partnership culture, which is key to HImPs, was described as “insufficiently 
developed to enable partnership agencies to feel secure in pooling resources, 
especially as they have other competing and non-health related priorities”.   
Other tensions to overcome included the difficulties in undertaking the 
consultation exercise and taking account of available research, given the time-
scale in which the HImP document has to be produced. 
 




Twenty-seven (40%) of questionnaire respondents said that they would be 
willing to participate in a semi-structured telephone interview and of those a 
sample of ten respondents were chosen; that is, 37% of those who agreed to 
an interview.  Two main criteria were used to choose the HImP leaders for the 
telephone interviews: (i) that they provided considerable feedback in the open-
ended section of the postal questionnaire and/or; (ii) because they raised some 
economic evaluation issues in the postal questionnaire that we were interested 
to explore further.  The respondents interviewed included those from a broad 
range of health authorities including rural communities, metropolitan regions, 
health authorities with HAZ, and those with an above average socio-economic 
rating. 
 
The majority of questions put to each HImP representative were based on their 
responses to the postal questionnaire and the aim was to obtain more detailed 
answers to responses of particular interest.  Additionally, at the time that the 
telephone interviews were undertaken, some preliminary analysis of the postal 
questionnaire results were available and this allowed the interviewees to 
explore some emerging themes in more depth. 
 
Based on the postal questionnaire results, six main themes were investigated: 
 
♦  the interviewee’s understanding of the meaning of health improvement and 
methods to achieve it; 
♦  the definition of evidence used in the study and where evidence might be 
used; 
♦  the complexities involved with decision-making; 
♦  the role of economics evidence in the development of the HImP; 
♦  the role of the inter-agency relationships; 
♦  the public’s involvement in the HImP. 
 
All the HImP leaders interviewed were enthusiastic about their HImP and the 
answers provided were helpful in providing explanations about the work that 
had been undertaken to produce the current HImPs.  Some respondents also 
gave suggestions about how the HImP might look in the future and the 
amendments and changes that could be made to improve the HImP.  From the 
answers given it was clear that most HImPs are still in the early stages of 
development and that, to date, changes in care provision made as a result of 
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that, over time, service re-configuration would be undertaken to re-orientate 
provision, with the aim of maximising health improvement. 
 
5.2.2  Defining and achieving health improvement 
 
From the postal survey results it was clear that respondents thought that health 
improvement is an important objective of the HImP.  In the interviews the 
concept of health, its determinants and health improvement were explored.  It 
was found that the definition varied across respondents and overall no clear 
understanding was achieved of what the terms mean. 
 
A few respondents mentioned that within the NHS there is pressure to deliver 
on health and yet the HImP is designed to be more encompassing, including 
wider socio-economic objectives relating to health.  It was suggested that the 
NSFs that underpin some of the national health improvement objectives tend to 
be medically driven and that the goals set are primarily driven by short-term 
concerns.  In contrast, it was argued that the socio-economic approach to the 
provision of care tends to take place and have an impact on health over a 
longer time frame.  Therefore, there might be some overall tensions in those 
objectives that have been set.  One interviewee mentioned that the HImP is a 
dynamic policy and that its introduction has provided a positive impetus for 
change and the right organisational framework for health improvement.   
Longitudinal analysis over a number of years will be important in ascertaining 
whether the HImP is a successful vehicle for improving health. 
 
While there have been a number of changes in health policy and administration 
over time, the maxim of financial control and keeping to budget remains 
constant.  Linking evidence to quantifiable targets appears the most powerful 
approach for driving home targets for health improvement.  The impetus to 
deliver and demonstrate tangible outcomes was strong, as was the call for 
accessible evidence to back up action plans. 
 
5.2.3 Targeting  evidence 
 
A few clear messages emerged with respect to the evidence base underlying 
HImPs.  First, evidence takes time to uncover and incorporate within the HImP 
process, so the evidence base of the HImP is expected to improve over time.  It 
was suggested by some interviewees that at present much evidence has been 
used in a re-active way to support current practice,  rather than a pro-active way 
to establish best practice.  It is not clear what is the most appropriate use of 
evidence.  Due to the short time horizon over which those involved in the HImP 
had to produce the document, the most immediate task was to present 
evidence to support what it was possible to achieve and not necessarily what 
was best value for money.  Of course, over the longer term the objective is to 
make a difference to the health of the community, based on the available 
evidence. 
 
Interviewees were keen to demonstrate value for money when drawing up the 
HImP, but for many it was never the expectation that the HImP would be Use of Economic Evidence in the Design of HImPs 
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systematically rooted in evidence.  Instead the HImP was seen as a composite 
of information, including a multitude of action plans relating to service provision.  
For the agencies collaborating in the HImP, common objectives are needed to 
give it direction.  The HImP provides an incentive for partnership and the 
interviewees thought that its introduction has created an impetus for change 
that has been met with much good will. 
 
A second issue, that was raised several times, concerned the nature of 
evidence and the way in which it was disseminated.  Evidence needs to be 
clear and understandable to people who have different professional 
backgrounds.  Most interviewees argued that the current evidence base tends 
to be medically driven.  For instance, the NSFs are rooted in medical evidence 
and were central to producing the HImP.  It was argued that less evidence was 
available on issues relating to the broader agenda of health care, such as 
environmental determinants of health.  Economic evidence was thought to be 
beneficial, though the information is not as accessible as it needs to be to make 
the maximum impact. 
 
A third theme was that HImP producers take a fairly heterogenous approach to 
the use of evidence in the production of their HImP.  While there were a 
number of “must dos” issued centrally as statutory requirements, that all HImP 
producers acted upon, the degree to which local evidence was used in a 
bottom-up approach varied considerably.  On the one hand there was a high 
degree of centralisation, either with the HImP boards playing a key role in the 
direction of the HImP, or evidence from the central bodies issuing national 
targets leading the direction of the HImP.  Alternatively, at the other end of the 
spectrum, action plans were designed based on a considerable degree of 
community consultation, either with the PCGs/Ts or with the public. 
 
Some interviewees mentioned that the guidance from NICE is a potentially 
valuable instrument for bringing good economic evidence to bear, although at 
the time of producing the second HImP little NICE guidance was available.  It 
was felt that the work of bodies such as NICE will help to reduce duplication of 
research effort, by collating and synthesising information centrally and then 
disseminating the information in a top-down fashion.  However, one respondent 
pointed out that there are three pronouncements made by NICE: definitively 
yes, or definitely no, or provide an intervention only under certain conditions.  
Announcements have so far tended to be in the latter, grey area, the 
consequence being that more decisions are devolved to the local level.   
Another interviewee said that any pronouncements to provide interventions 
made by NICE became “must dos” immediately and yet the resources needed 
to enact such decisions are not necessarily available.  To date there has been 
a high degree of media interest in the pronouncements made and this makes it 
even more difficult to ration care.  The suggestion was that earmarked funds be 
made available to enable health care providers to meet any sanction that was 
given to provide a service.  Since this research was undertaken, the 
government has announced that NICE guidance is to become mandatory, 
although there is still no intention to provide earmarked funding.  Nevertheless, 
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5.2.4  Some complexities associated with decision making 
 
Several interviewees drew attention to the complexity of decision making.  One 
point highlighted was the need to make a distinction between preferences at 
the level of the individual, which were seen as primarily quality focused, as 
compared to a more quantity-focused agenda at the collective level.  One 
cancer HImP lead pointed to the emotive nature of cancer illness and that this 
compounds the difficulty of making rational decisions.  Referring to cancer 
patients, the interviewee said that on an individual basis, day to day needs are 
expressed by cancer patients, for instance the demand for quality-focused 
services such as complementary medicine.  However, when expressing their 
views in the presence of clinicians, patients tended to defer to professionals 
and their arguments tended to shift towards a focus on the quantity of services 
provided, based on the idea that more was better for the good of the community 
as a whole.  To overcome the potential problem of the under representation on 
user reviews, some cancer HImP leads have set up workshops for patients and 
voluntary organisations to help them to identify their needs, to empower them 
and to organise a remit to improve the services received.  The aim is to 
encourage such groups to formalise their agenda for action so that issues of 
concern may be given a higher profile and therefore have the potential to be 
translated into practice.  It was stressed that consultations with the public can 
be quite costly, particularly in terms of time, so that it was important to consider 
this when organising such activities. 
 
5.2.5  The role of economics 
 
From the interviews it emerged that HImP leaders had used some economic 
frameworks in their approaches to decision making.  Some HImP leaders had 
produced pro-formas to prioritise interventions for different disease areas and 
within these they included requests for economic evidence such as information 
on health gain and value for money.  Some others had used SWOT (Strengths, 
Weaknesses, Opportunities and Threats) analysis.  This is a management tool 
and does not necessarily include costs.  However, it does consider the positive 
and negative aspects of providing care and facilitates a discussion of choice, 
much like economics.  One HImP group had undertaken economic-type 
exercises to help decide on priorities.  The HImP board had been presented 
with a fixed budget and were asked what services would be provided within 
budget, then the fixed budget was reduced.  The aim of the exercise was to 
encourage decisions to be made under increasingly constrained conditions and 
to drive home the rationing problem.  Similarly, one Health Authority had used 
Programme Budgeting Marginal Analysis to illustrate the distribution of 
expenditure on health care goods and services. 
 
One interviewee indicated economics could be used to provide positive 
messages on resource allocation, as described in the box below.  The same 
interviewee also called for more research on organisational and delivery 
aspects of care.  Associated with this, it was argued that little evidence is 
available on the impact on other services of implementing the results of cost-Use of Economic Evidence in the Design of HImPs 
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effectiveness analyses, or on the impact on other objectives of the HImP such 
as equity in health. 
 
“There is a dearth of economic-based evidence – particularly the 
evidence base on disinvestment.  Disinvestment is seen as a negative 
thing – whereas in economic terms it is a positive thing as the resources 
are then re-allocated to more beneficial use.” 
 
A few interviewees mentioned the importance of resource mapping and the 
need to link it to health needs information as well as the likely demand for 
services.  One interviewee added that while there may be economic studies 
available, the consistency and generalisability of them was often lacking and 
there was a call for contextual analysis to be applied so that the evidence could 
be made relevant to a specific setting. 
 
5.2.6  The role of the public in the HImP partnership 
 
Since its inception, the inclusion of public opinion was held to be a key objective 
of the HImP process.  Within the HImP partnership, a number of HImP leaders 
spent a great deal of time consulting with the public and with specific patient 
groups.  It was emphasised that it is important to be aware of what involving the 
public means.  Interviewees argued that while the Government wants to show 
members of the public that it is listening to their demands, at the individual level 
the patients do not always feel reassured.  By engaging the public, more 
difficulties are made explicit and potentially more work is generated.  Therefore, 
the incentive mechanism to consult the public needs to be carefully thought out. 
 
HImP leaders from health authorities with varied geographical distributions of 
the population were interviewed.  The heterogeneity of evidence underpinning 
HImPs may well reflect the fact that those involved in producing the HImP were 
keen to orient the document to the needs of the local community.  In sparsely 
populated areas, access to care was stated as an important concern.  In health 
authorities based in cities, a chief objective was the need to prioritise the 
priorities – particularly in areas including HAZs, where the level of poverty and 
ill health is highest and where the variation in health status within health 




In summary, three main suggestions were made.  First, HImPs need to 
embrace a broader model of care and clearer definitions of objectives would 
enhance this.  Second, incentives which link evidence to practice would help to 
ensure “best HImP practice”, however defined.  Third, on a practical level, 
evidence needs to be more accessible and user friendly.  For instance, 
economic evidence was thought to be very important but more is needed to 
inform the policy decisions that have to be taken.  For instance, there needs to 
be more information on organisational and delivery aspects of provision.  A 
number of interviewees argued that those involved in HImPs found it helpful Use of Economic Evidence in the Design of HImPs  32 
when evidence was collated and disseminated from the centre, as long as they 
were given the flexibility to adapt the information to allow for local interpretation. 
 




A random sample of 26 (25%) HImP documents were obtained in order to 
review whether reference was made to the use of any evidence in the 
development of the HImP and if so, what type of evidence.  The overall aim 
was to build up a picture of the kinds of priorities for delivery of care that were 
being proposed under the HImP umbrella and to gain an idea of the extent to 
which priorities and target setting were linked into the evidence base of the 
HImP. 
 
Overall, very few HImP documents made any significant reference to the 
evidence.  Reference to external evidence was particularly sparse.  Most 
HImPs extended their brief beyond those disease areas that were statutory 
requirements and the number of priorities within each HImP varied from six to 
twenty, the average number being twelve.  As illustrated in the table below, 
besides CHD, cancer and mental health care, other examples of HImP 
chapters include a focus on children and young people, drugs and substance 
misuse, people with learning and physical disabilities and chronic diseases. 
 
Thirteen (50%) HImPs documents were reviewed for the use of cancer 
evidence and 13 (50%) HImP documents were reviewed for CHD evidence.  Of 
the 13 HImPs documents reviewed for CHD evidence, at the national level 12 
(92%) referred to the NSF on CHD, three (23%) referred to the national 
priorities guidance for CHD, two (15%) referred to a review on invasive and 
tertiary cardiac services, two (15%) referred to the “Tobacco Kills” White Paper 
and one (8%) HImP referred to the stroke strategy or the exercise strategy. 
 
Of the 13 HImP documents reviewed for cancer evidence, at the national level 
four (31%) mentioned the Calman-Hine Report and the Clinical Outcomes 
Guidance (COG), one (8%) mentioned the tobacco White Paper “Smoking Kills” 
and the circular HSC 1998/999 in relation to local strategies on smoking and 
three (23%) mentioned the “New NHS: Modern and Dependable” document. 
Reference to published literature was made in six (46%) of the 13 HImP 
documents reviewed for cancer evidence.  For the HImPs reviewed for cancer 
evidence, reference was made to the following published literature: government 
sources such as “Our Healthier Nation” for priority areas within the HImP, 
Modernising Health and Social Services for National Priorities Guidance and 
the NHS Executive document on colorectal cancer.  Other types of evidence 
included the Calman-Hine report on cancer guidance, health action zones, the 
health survey for England smoking rates, standard mortality rates and the HEA 
Sun Awareness Campaign.  For the studies reviewed for CHD evidence, the 
following documents were mentioned: Saving Lives: Our Healthier Nation, the 
NSF, census data and information from the British Cardiac Society. Use of Economic Evidence in the Design of HImPs 
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Table 18:  Disease areas covered in the HImPs 
 
Disease, prevention or treatment area included as a 
chapter in the HImPs (% of HImPs covering area) 
Number of times a disease, 
prevention or treatment area was 
included as a chapter in the HImPs 
Heart disease (100%) 
Cancer (96%), Mental Health care (96%) 
Children and young people (89%) 
Accidents (84%) 
Old people (77%) 
Over 20 times 
Drugs and substance misuse (73%) 
People with learning disabilities (65%), Sexual health (65%) 
People with physical disabilities (54%) 
Access to services (46%) 
Inequalities (39%), Primary care, (39%), Dental care (39%) 
Between 10 and 20 times 
Carers (35%) 
Chronic disease (e.g. diabetes) (31%), Smoking (31%) 
Homelessness (27%), Crime (27%) 
Ethnicity (19%), Acute and community health (19%) 
Palliative care (12%) 
Continuing professional development (8%), Employment 
(8%), Perinatal mortality and maternal health (8%), Asthma 
(8%) Community disease control (4%), Refugees (4%), 
Education (4%), TB (4%), Health promotion & protection 
(4%), Renal & gut disorders (4%), Health and social services 
(4%), Intermediate care (4%) 
Less than 10 times 
 
 
References to local studies included local guidance on secondary prevention in 
CHD, clinical information systems in a cardiac unit and local audits and Public 
Health reports for both CHD and cancer.  Some health authorities were acting 
upon Regional collection of evidence, for instance the “Health of Londoners 
Project”.  However, for a number of HImPs no reference was made to such 
evidence at all. 
 
The introduction of the HImP sets the context for what is to follow.  In 34% of 
cases (nine HImPs) no mention of economic terms were made in the 
introduction.  Terms that may have some economics connotations included: 
financial frameworks for HImPs, the use of Health Economy boards at the 
decision making level, Primary Care Investment Plans and Joint Care 
Investment Plans, the presence of limited funds, SaFFs to link HImPs priorities 
and planning cycles.  Only two documents mentioned cost-effectiveness 
explicitly.  Besides this “careful management of overall NHS resources” was 
mentioned as was the need for “balancing costs and outcomes and achieving 
best value”. 
 
For the HImPs where the use of CHD economic evidence was being explored, 
one document mentioned cost-effectiveness evidence to reduce smoking 
prevalence, one mentioned local priorities for capital development, one cost 
and one affordability.  Nine (70%) of HImPs documents reviewed for CHD 
evidence did not use any economic-related terms. 
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For the HImPs where we looked at the economic evidence for cancer, 10 (77%) 
did not refer to any economic evidence at all, one mentioned modernisation 
funds for the development of patient care pathways, one resources and one 
financial frameworks. 
 
Evidence from national targets was mentioned in seven (54%) of the HImP 
documents reviewed for CHD evidence.  All of these mentioned the national 
target relating to a decrease in death rates from CHD/stroke in under 75 year 
olds by 20% or more by 2010. 
 
References were made to the following cancer national target evidence: four 
(31%) mentioned increasing cervical cancer screening to an average of 80% by 
2002 and one (8%) mentioned a decrease in smoking. 
 
Local targets for cancer that were mentioned included; three (23%) relating to 
local gynaecology services development of patient care pathways, two (15%) 
relating to the London plan, two (15%) relating to coloscopy programme.  For 




The aim of this project was to investigate the role of evidence in the design of 
HImPs, particularly economic evidence.  There have been a few research 
projects on HImPs, but none have looked specifically at the contribution of 
evidence or the use of economics.  For each of the surveys conducted as part 
of this research, it was clear that HImP leaders think that evidence is an 
essential ingredient to underpin service delivery decisions. 
 
It must be recognised that surveys have inherent weaknesses, in that 
respondents may give the answers they feel they should give, rather than 
answers reflecting reality.  Therefore, an analysis of HImP documents was 
undertaken. 
 
Within most HImP documents some references were made to national targets, 
especially those provided through the National Service Framework (NSF).  The 
NSF will have been based on evidence from numerous uncited sources.  The 
large majority of survey respondents argued that the NSF provides useful 
guidance to formulate service delivery, assuming some flexibility of 
implementation at the local level.  Beyond this, the references to evidence in 
the HImP documents was sparse, although it might not have been the intention 
of those writing the documents to cite the evidence in detail. 
 
Bearing these limitations in mind, the main conclusions of this research are as 
follows: 
 
(i)  HImPs are seen as having multiple objectives 
 
Whereas the improvement of the health of the population is viewed as the 
prime objective of HImPs, other important objectives are to reduce health Use of Economic Evidence in the Design of HImPs 
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inequalities and to develop partnerships, such as encouraging joint working 
arrangements.  For many, the process of developing HImPs was as important 
as the outcome, particularly since HImPs are in their infancy.  Therefore, we 
might expect to see a trend towards more measurable targets and the more 
explicit use of evidence in the future. 
 
Many respondents, particularly those from a public health background, saw the 
process of developing HImPs as a way of stressing the broader socio-economic 
determinants of health, as opposed to the ‘medical model’ of health and health 
care.  However, some of their efforts to stress broader socio-economic 
interventions to improve health were thwarted by the relative lack of evidence 
on costs and effects for such interventions. 
 
(ii)  The notion of evidence is interpreted broadly 
 
It is clear from the research that traditional notions of evidence, namely data 
drawn from classical research studies and published in the literature, do not 
encompass the range of inputs to the design of a HImP.  Many of the inputs 
relate to national guidance and local professional opinion, which in turn might 
be based on data from research studies.  Therefore, it is important to have a 
broad definition of what constitutes evidence.  The distinction used here, 
between internal and external evidence, proved useful in exploring 
respondents’ views on the use of evidence in developing HImPs. 
 
(iii)  Basic concepts of economics are well-understood if not always 
applied 
 
Most respondents fully understood the basic notions of economics and the 
need to make tough choices when faced with a budget constraint.  However, 
the level of access to economic analyses and economics expertise was low.  
Therefore, even where economic studies did exist, it was not clear how they 
could be interpreted and used. 
More importantly, given the various constraints operating locally (see below), 
most respondents found it difficult to operationalise economic concepts in 
decision making, even if they wished to do so.  There were, however, some 
notable exceptions to this (discussed below). 
 
(iv)  Local constraints greatly influence the development of HImPs   
 
Most respondents commented on the speed at which their HImP had to be 
developed and that time limitations precluded extensive searches for evidence.  
In addition, several key resources were not available, or in a limited supply, at 
the local level.  This made it impossible to search for, synthesise and interpret 
evidence, particularly economic evidence.  Economic evidence had the 
additional problem that it might not transfer easily from one setting to another 
and therefore it needed to be interpreted in the light of the local context. 
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Political acceptability is also an important criterion in judging health care 
interventions at the local level.  Therefore, external evidence is inevitably 
merged with local professional and public opinion when deciding upon priorities. 
 
(v)  National guidance is very influential in the design of HImPs 
 
It was clear from the responses that most health authorities took very seriously 
the guidance embodied in the NSFs and (more recently) pronouncements from 
NICE.  Respondents assumed that the evidence base of such guidance was 
sound, although the guidance itself may not always have utmost relevance, 
given local circumstances.  In particular, health authorities wanted more advice 
on how to implement NICE guidance locally. 
 
Given the current constraints, in time and expertise, at the local level, central 
initiatives are therefore critical to the HImP process.  These include not only the 
issuing of guidance through NICE and the NSFs, but also initiatives in the 
generation, synthesis and dissemination of evidence through the Health 
Technology Assessment (HTA) programme, the Cochrane Collaboration and 
bodies such as the NHS Centre for Reviews and Dissemination. 
 
A number of these issues are discussed in more detail below and then, in 
Section 7, a number of research and policy implications are identified. 
 
6.1  The role of internal and external evidence 
 
While more demands for additional external evidence were made, in practice 
HImPs tend to be based both on internal and external evidence.  The latter 
tends to be less well documented and less explicit.  In terms of external 
evidence, while many HImP leaders were keen to use more local data, it 
appears that there needs to be some restructuring of data collection to allow 
more fruitful analysis to be undertaken.  Information systems are needed to link 
local health care needs with national targets and guidance (Kilner et al, 1999).  
While existing evidence is typically limited, solutions tend to be pragmatic, 
making the best use of the available evidence.  As Davey Smith et al (2000) 
argue, an “important question (needs to be asked) about what sort of data 
provide appropriate evidence for particular types of decisions”, and they see a 
potential “mismatch between evidence and policy”.  Instead of focusing on how 
policy informs evidence, Macintyre et al (2001) approached the issue from the 
opposite direction, by exploring how evidence can be used to inform health 
policy.  In practice, there needs to be an interactive relationship between 
researchers and funders with researchers and policy experts informing each 
other.  There is also a need to generalise results beyond the confines of the 
research programmes on which they are based.  Also, most research tends to 
focus on individual level determinants of health (e.g. medical interventions) 
rather than population level determinants and, as Davey Smith et al argue, the 
determinants of each may differ (Davey Smith et al, 2000). 
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6.2  Use of economic evidence and best practice 
 
Generally speaking, most health authorities made some use of economic 
evaluation evidence within the HImP, and the large majority of questionnaire 
respondents said that economics had a valuable contribution to make when 
applied to health care delivery.  There was also some infrequent use of 
sophisticated forms of economic evaluation, using outcomes such as QALYs or 
DALYs as a measure of the “relative efficiency of health gain potential within 
and across each of the sectors”.  
 
Other examples of the influence of economic thought included the use of 
Programme Budgeting and Marginal Analysis (PBMA) and the use of pro-
formas designed to encourage the systematic use of evidence.  Examples of 
the type of information required in one HImP priorities matrix included 
demonstration of value for money, for example cost per QALY values or a given 
cost per life year gained.  Within their HImP another health authority suggested 
a number of criteria on which to assess the relative priority of proposed NHS 
developments and these included a finance section containing the following 
questions: 
 
•  What are the revenue costs and / or savings? 
•  How is it proposed to finance any net revenue cost? 
•  What are the capital and / or non-recurrent costs and how is it proposed to 
account for them? 
 
Additionally a section on efficiency was included: 
•  Have the costs and benefits of the status quo been considered? 
•  What is the added value, in terms of cost per new outcome? 
•  Have other options been considered? 
 
Only in a small minority of cases did HImP leaders state that they thought 
economics had only limited use in the design of HImPs and, of these, a number 
said that they had not used economic evidence due to poor availability of local 
data and external evidence.  Most respondents who said that the use of 
economic evidence was limited also said that they would have used the 
information: (i) had it been available and; (ii) if the expertise to interpret study 
findings was available. 
 
 
7.  Research and Policy Implications 
 
The results of this research lend considerable support to a number of research 
and policy initiatives that are already underway, such as the development of 
various forms of national guidance and the dissemination of evidence-based 
practice.  They also suggest some others.  The main implications are as 
follows: 
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(i)  The evidence base of national guidance should be maintained, if 
not strengthened 
Given local constraints on time and resources, those developing HImPs are 
only too willing to embrace national guidance.  Therefore, this represents the 
major vehicle for improving the evidence base of local decisions.  It is 
important, therefore, that the evidence base of NSFs and NICE guidance 
remains strong and that this evidence base includes economic evidence. 
 
(ii)  Efforts should continue to generate, synthesise and disseminate 
evidence on a national level 
Only on rare occasions will there be opportunities to undertake a 
comprehensive review of the evidence at the local level.  Therefore, the 
considerable efforts already made to generate, synthesise and disseminate 
evidence through the NHS R&D programme are critical to improving the 
evidence base of local decisions.  Those developing HImPs were particularly 
appreciative of readily accessible reviews of cost-effectiveness evidence and 
were less likely to consult academic journals. 
 
The synthesis and dissemination of economic evidence presents some 
particular challenges, as local factors might influence whether a particular 
intervention is cost effective.  Thus, the interpretation of economic evidence 
from another setting can pose difficulties.  Therefore, more effort should be 
placed on understanding how local factors influence cost-effectiveness and the 
ways in which local decision makers can better interpret economic study results 
in their own circumstances. 
 
(iii)  Quantifiable targets (for health improvement) and the role of 
evidence in priority setting need to be stressed 
Many respondents acknowledged that, as the learning curve in producing 
HImPs was climbed, there would be less emphasis on process issues and more 
on outcomes.  They also felt that evidence would be used more explicitly.  The 
HImPs differed greatly in terms of their emphasis on quantifiable targets and 
mechanisms to consider evidence in a formalised manner.  Some of the more 
promising local initiatives, such as the use of proformas or cost-benefit 
matrices, should be studied further in order to ascertain whether they could be 
more widely adopted. 
 
When progress has been made in setting national targets for health outcomes 
within the context of the performance assessment framework, HImPs may be 
an appropriate vehicle for monitoring local progress in advancing national 
targets. 
 
(iv)  The local role in assembling evidence needs to be clearly defined 
and adequately resourced 
Whilst most of the teams developing HImPs relied on national guidance, such 
guidance clearly needs to be interpreted in the light of local circumstances.   
Therefore, a clearer specification is required of the local demographic, 
epidemiological and financial information necessary to produce the HImP.   
Several of the HImP leaders welcomed initiatives such as Public Health Use of Economic Evidence in the Design of HImPs 
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Observatories, which they felt would greatly assist them.  However, the 
responses to the questions about resources to produce the HImP indicated 
some were in short supply, in particular economics expertise. 
 
(v)  Efforts to educate health care professionals in evidence-based 
medicine and economics should be maintained, or strengthened 
It was clear from the surveys that local professional opinion, especially clinical 
opinion, is central to the production of the HImP and the development of 
priorities.  This emphasis will remain, even if the efforts outlined above to 
strengthen the evidence-base of national guidance and to disseminate 
evidence, are made. 
 
Therefore, it is important that, through educational programmes, clinicians have 
an adequate appreciation of the principles of evidence-based medicine and 
economics.  This will maximise the possibility that their opinions, when given, 
will embody these principles. 
 
(vi)  More research should be undertaken into the cost-effectiveness of 
broader socio-economic interventions to improve health 
Several respondents talked about the tension between the ‘socio-economic’ 
and ‘medical’ models of health and the fact that, in assigning priorities, medical 
interventions had precedence due to their superior evidence base.  Therefore, 
more attention should be placed on evaluating some of the broader, inter-
agency interventions that are identified as part of the HImP process. 
 
(vii)  The research and policy implications of this study also need to be 
reviewed in the light of the recent organisational changes in the 
NHS, in particular the creation of strategic health authorities and 
the developing role of PCG/Ts 
The new strategic health authorities will cover large populations and will 
therefore not be the place where local plans are developed.  Thus the task of 
producing HImPs, or some variant on these, will fall to the PCG/Ts. 
 
The major issue raised by these organisational changes, in relation to this 
study, is whether PCG/Ts will have the level of resource and expertise to 
gather, synthesise and interpret evidence.  In particular, what skills are they 
likely to have in public health or economics?  This study showed that such 
resources were often in limited supply, or absent, in health authorities. 
 
As the organisational changes progress, some of these issues may be 
addressed.  In the meantime, however, PCG/Ts are likely to be even more 
reliant on the national guidance than were the health authorities in our survey.  
This suggests that many of the policy implications identified above have even 
more relevance, given the organisational changes that are taking place. 
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9. Appendices 
 
9.1:  Questionnaire on the use of evidence in the design of HImPs 
 
 
THE HEALTH IMPROVEMENT PROGRAMME 















Funding body: Department of Health 
 
Survey conducted by: Centre for Health Economics, University of York 
Research team: Mike Drummond, Dave Smith and Helen Weatherly 
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ABOUT THIS QUESTIONNAIRE 
 
QUESTIONNAIRE RATIONALE 
The Centre for Health Economics at York University is undertaking research funded by 
the Department of Health, on the role of evidence in the design of HImPs.  In particular, we are 
interested the use of economic (ie. cost-effectiveness evidence).  To this end, a copy of this 
questionnaire has been sent to each Health Authority in England.  As a key output of our 
research a report will be produced which we will send to you later this year.  We hope that this 
report will be of interest to you, as we aim to present a picture of the evidence base of HImPs for 
all Health Authorities in England. 
 
FOCUS OF QUESTIONNAIRE 
  We are particularly interested in two disease areas within the HImP, namely coronary 
heart disease and cancer, and we will ask you to choose one and to focus on it for some of 
your answers.  If necessary, feel free to consult one or more colleagues who were closely 
involved in the production of the HImP in the given disease area. 
 
OUR DEFINITIONS OF EVIDENCE 
The main aim of this questionnaire is to explore what evidence ought to be used and 
what evidence is used in the design of HImPs.  For the purposes of this survey we take the word 
evidence to mean “any information available for guiding action”.  We make a distinction between 
evidence which is internal or experiential, that is based on professional opinion and tacit 
knowledge, as compared with external or empirical knowledge which is based on research 
from primary and/or secondary studies e.g. guidelines or published studies. 
 
CONFIDENTIALITY 
The questionnaires that are returned to us will be treated in complete confidence and 
only the research team at the University of York (see Page 1 for the researchers involved) will 
have access to your response.  No explicit reference to your Health Authority will be made in the 
report unless your permission is sought in advance. 
 
WHAT TO DO NOW 
We would be grateful if you could complete this questionnaire and return it to us in the 
freepost envelope provided.  To enable us to write a report for autumn it would be helpful if you 
returned your completed questionnaire within the next fortnight, that is by Friday 6
th of October 





Your job title.................................................................................................................. 
 
Academic and professional qualifications (please include short courses on e.g. health 
economics...................................................................................................................... 
...................................................................................................................................... 
...................................................................................................................................... Use of Economic Evidence in the Design of HImPs  44 
Q.1  In your view, within your HImP what are the objectives of HImPs? How important 
are the following? (Please tick one box in each row) 
    (i) Very         (ii) Quite              (iii) Limited     (iv) Not 
        important       important               importance     important 
1a To improve health      ❑             ❑              ❑               ❑  
 
1b To encourage partnership    ❑             ❑              ❑               ❑  
in the provision of care 
 
1c To reduce health inequality  ❑             ❑              ❑               ❑  
 
1d To focus on efficient        ❑             ❑              ❑               ❑  
provision of care 
 
1e To identify local priorities in   ❑             ❑              ❑               ❑  
health care provision 
 
1f To organise and co-ordinate  ❑             ❑              ❑               ❑  
health care provision 
 
1g To provide a performance  ❑             ❑              ❑               ❑  
management framework 
 
1h Other (Please specify)   ❑             ❑              ❑  
............................................................................................................................... 
 
Q.2  In your view what was the prime objective of the HImP that you were involved in? 
(Please tick one of the boxes below. You will note that the objectives mentioned here are a 
repeat of the objectives in Q.1 above. The aim of this question is to decide what is the most 
important objective.) 
2a To improve health    ❑    2b To encourage partnership    ❑  
      in the provision of care 
 
2c To reduce health inequality  ❑    2d To focus on efficient provision of   ❑  
      c a r e  
 
2e To identify local priorities in  ❑    2f To organise health care provision  ❑  
health care provision     
 
2g To provide a performance  ❑    2h Other...............................................………… 
management framework Use of Economic Evidence in the Design of HImPs 
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Q.3  Apart from Health Authority Staff, who was consulted in the production of the 
HImP that you are involved in? (Please tick the appropriate box/es) 
 
Local Authority Departments: 
❑   3a Housing     ❑   3b Education 
❑   3c Transport     ❑   3d Social Services 
❑  3e  NHS  Trusts     ❑   3f Primary Care Groups/Trusts 
❑   3g Community Health Councils   ❑   3h Voluntary bodies 
❑   3i Local  people     ❑   3jOther (Please specify)....................... 
 
 
Q.4  Overall, would you say the internal/external evidence base of the 2000-2003 HImP 
that you are involved in met your expectations? (see P2 for our definitions on evidence) 
(Please tick one box) 
 
4a Completely satisfied ❑      4b Quite satisfied  ❑  
4c Not very satisfied  ❑      4d Not at all satisfied  ❑  
 
 
Q.5  Please can you tell us why you answered “completely satisfied”, “Quite 







Q.6  Do you think that economic evidence (relating to issues such as costs or cost-
effectiveness) should influence the design of HImPs? (Please tick one box) 
 
5a Yes, very much so  ❑      5b Yes, quite a bit    ❑  
5c Only marginally  ❑      5d No     ❑  
 
 
Q.7  Please can you tell us why you answered “yes, very much so”, “yes, quite a bit”, 









FOR THE REMAINDER OF THIS QUESTIONNAIRE PLEASE FOCUS ON EITHER 
CORONARY HEART 






Q.8  Please indicate a choice of: 
 
EITHER  8a Coronary Heart Disease  ❑    OR  8b Cancer  ❑  
 
Did you make your choice because (please choose one): 
 
❑   8c.  You have greater knowledge of the programme area in your HImP 
 
❑   8d.  The evidence base is relatively strong for the programme area concerned 
 




❑   8f:  No particular reason Use of Economic Evidence in the Design of HImPs 
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Q.9    For the HImP that you were involved in, how important were the following 
sources of external / empirical evidence in deciding what Coronary Heart Disease or 
Cancer services to provide? (Please tick one box in each row) 
 
(i) Very         (ii) Quite         (iii) Limited    (iv) Not       (v) Did 
important       important           importance     important    not use 
 
9a National Service Framework ❑          ❑          ❑           ❑          ❑  
guidelines 
 
9b NICE guidance    ❑          ❑          ❑           ❑          ❑  
 
9c Government publications e.g. ❑          ❑          ❑           ❑          ❑  
guidance on the commissioning 
of cancer services for improving 
colorectal cancer 
 
9d Clinical guidelines e.g.   ❑          ❑          ❑           ❑          ❑  
choiceof ACE-inhibitors in the  
primary care management of  
adults withsymptomatic heart failure 
 
9e Guidance from professional  ❑          ❑          ❑           ❑          ❑  
associations e.g. the Royal College of Surgeons 
 
9f Secondary sources     ❑          ❑          ❑           ❑          ❑  
(e.g. effective Health Care Bulletins, Bandolier) 
 
9g Published cost-effectiveness ❑          ❑          ❑           ❑          ❑  
analyses e.g. screening for 
hypertension 
 
9h Work commissioned to   ❑          ❑          ❑           ❑          ❑  
academic researchers 
 
9i Work commissioned to   ❑          ❑          ❑           ❑          ❑  
management consultants 
 
9j General published literature   ❑          ❑          ❑           ❑          ❑  
(e.g. journal articles 
 
9k Other (Please specify).................................................................................................... Use of Economic Evidence in the Design of HImPs  48 
Q.10  For the HImP programme that you have chosen to focus on, how important were 
the following sources of internal evidence in deciding what Coronary Heart Disease / 
Cancer services to provide to meet the priorities identified? (Please tick one box in each 
row) 
 
    (i) Very         (ii) Quite               (iii) Limited     (iv) Least 
        important       important               importance     important 
 
10a Clinical opinion    ❑              ❑             ❑               ❑  
10b Health care managers  ❑              ❑             ❑               ❑  
       opinion 
10c Academic researchers  ❑              ❑             ❑               ❑  
       opinion 
10d Public/lay opinion    ❑              ❑             ❑               ❑  
10e Patient advocacy groups  ❑              ❑             ❑               ❑  
 
10f Other (Please specify).......................................................................................................….. 
 
 
Q.11  Generally speaking, we are interested to know about the type of evidence used to 
decide which health care interventions to focus on (for either Coronary Heart Disease or 
Cancer). Would you say the evidence was internal evidence OR external evidence (see P2 
for our definitions on evidence) (Please tick one box below only) 
 
11a  All internal 
evidence 
11b More internal than 
external evidence 
11c More external than 
internal evidence 
11d All external evidence 
 
❑      ❑      ❑      ❑  
 
 
Q.12  Who was given the job of finding information? (Please tick one box in each row) 
 
(i) Yes     (ii) No 
12a Yourself      ❑      ❑  
12b Information officer/s      ❑      ❑  
12c Researcher/s     ❑      ❑  
12d Clinician/s      ❑      ❑  
12e Administration  staff     ❑      ❑  
 




 Use of Economic Evidence in the Design of HImPs 
 
49 
Q.13  Did you find there was “satisfactory”, “limited” or “insufficient” supply of 
resources for the design of HImPs for the following resource examples? (Please tick one 
box in each row) 
 
Resource type       (i) Satisfactory   (ii) Limited              (iii) Insufficient 
13a Financial resources   ❑      ❑      ❑  
13b Information officer/s  ❑      ❑      ❑  
13c Health economist/s   ❑      ❑      ❑  
13d Epidemiologist/s   ❑      ❑      ❑  
13e Clinical resource/s    ❑      ❑      ❑  
13f Health services researcher/s ❑      ❑      ❑  
 
13g Other (please specify)................................................................................................... 
 
 
Q.14  Did you find the following types of economic evidence useful? 
(Please tick one box in each row) 
(i) Very         (ii) Quite         (iii) Limited    (iv) Not        (v) Did 
        useful          useful         use       useful          not use 
 
14a Discussion and advice from ❑          ❑          ❑           ❑          ❑  
economists 
 
14b Cost-effectiveness analysis  ❑          ❑          ❑           ❑          ❑  
information published as reports or in journals 
 
14c Reviews of cost-    ❑          ❑          ❑           ❑          ❑  
effectiveness in health care  
e.g. Effective Health Care Bulletin 
 
14dAdvice from such     ❑          ❑          ❑           ❑          ❑  
bodies as NICE 
 
14e Conferences where   ❑          ❑          ❑           ❑          ❑  
economic  evidence is discussed 
 
14f Other types of economic evidence  
(Please specify)........................................................................Use of Economic Evidence in the Design of HImPs  50 
Q.15  What was the method used for collecting evidence in the design of HImPs? 
(please tick one box in each row) 
 
 




15a Focus groups         ❑      ❑    ❑    ❑  
15b Interviews           ❑      ❑    ❑    ❑  
15c Questionnaires         ❑      ❑    ❑    ❑  
15d Literature searches        ❑      ❑    ❑    ❑  
15e Internet           ❑      ❑    ❑    ❑  
 
 
15f Other (Please specify) ................................................................................................ 
 
 
Q.16  Are you aware of any economic evaluations (e.g. cost-effectiveness studies) on 
either Coronary Heart Disease or Cancer that were used in the production of the HImP 
that you have chosen to focus on? (Please tick one box as appropriate) 
 
16a Yes         ❑    OR       16b No ❑  
 
 
Q.17  If you answered yes to Q.16 above, please provide references for the different 
sources of economic evaluation evidence listed below (Please provide references as 
appropriate) 
 
Source of evidence     Please  provide  an  example/reference 
 
17a Scientific  journals     …………………………………………............. 
17b A study you undertook yourself    …………………………………………............. 
17c A study you commissioned      …………………………………………............. 
17d Reports and working papers    ..……………………………………….............. 
17e On-line databases e.g. NHS EED    ..……………………………………….............. 
17f Databases e.g. OHE NEED      ..……………………………………….............. 
17g Internet      ..……………………………………….............. 
17h Conferences     ..……………………………………….............. 
17i Other (Please specify)     ..……………………………………….............. 
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Q.18  Did you decide on any of the following priority for action? 
 
IF CANCER IS YOUR CHOSEN FOCUS: (Please tick all that apply) 
     
18a  Increasing management of cancer care by specialist multidisciplinary teams  ❑  
18b  Beginning (or intensifying) smoking cessation and discouragement efforts    ❑  
18c  Concentrating cancer surgery to surgeons who demonstrate good results   ❑  
18d  Establishment of dedicated diagnostic/assessment services for gynaecological 
cancer within cancer units  ❑  
       





IF CORONARY HEART DISEASE IS YOUR CHOSEN FOCUS: (Please tick all that apply) 
 
18f  Increasing efforts to treat those (especially the elderly) with high blood pressure  ❑  
18g  Beginning (or intensifying) smoking cessation and discouragement efforts    ❑  
18h  Promoting  healthy  eating  lifestyle        ❑  
18i   Efforts  to  reduce  obesity         ❑  
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Q.20  What do you think the main barriers to using evidence in HImP design are? 
(Please tick any appropriate boxes)  
    (i) True        (ii) Quite true     (iii) Slightly true      (iv) Not true 
 
20a Relevant evidence is not     ❑              ❑             ❑               ❑  
available 
20b Evidence is available but it  ❑              ❑             ❑               ❑  
makes untenable assumptions 
 
20c Evidence is available but is 
not understandable / accessible ❑              ❑             ❑               ❑  
 
20d Evidence is available but   ❑              ❑             ❑               ❑  
consensus on whether to use it 
could not be reached 
 
20e There is not enough time    ❑              ❑             ❑               ❑  
to look for evidence. 
 
20e Too much information is  ❑              ❑             ❑               ❑  
available 
 




Q.21  What kind of evidence do you think would help to improve the decision making 
process when faced with a choice between different interventions for either Coronary 
Heart Disease or Cancer? (Please tick one box in each row) 
 
    (i) Very       (ii) Quite           (iii) Limited      (iv) Least 
        important       important            importance      important 
21a NICE guidance    ❑             ❑              ❑               ❑  
21b Government direction  ❑             ❑              ❑               ❑  
21c Management opinion  ❑             ❑              ❑               ❑  
21d Public opinion/focus groups ❑             ❑              ❑               ❑  
21e Clinical opinion    ❑             ❑              ❑               ❑  
21f Published evidence (e.g.   ❑             ❑              ❑               ❑  
journal articles) 
21g Other (Please specify)  ❑             ❑              ❑  
 
............................................................................................................................................ 
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Please indicate if, in principle, you would consider being involved in a semi-structured 
interview on the role of evidence in the design of HImPs. 
(please tick the appropriate box) 
 
❑  Yes  ❑  No 
 
 
Thank you for your comments and the time taken to 
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9.2  Pro-forma used to abstract information from the HImP documents 
 
Cancer/CHD HImP Pro-forma 
1. HImP Case Number ___ 
 
2. Disease Areas Covered in HImP (tick box of all that apply) 
❑  Cancer   ❑  Heart Disease    ❑  Mental Health 
❑  Accidents  ❑  Older People    ❑  People with Physical Disability 
❑  People with Learning Disability    ❑  Access to Services 







3. References to Specific Government Guidance in Cancer / CHD.  Quote 


















5. In the introduction, quote sentences with mentions of the following (or similar 
meaning words/phrases):Scarcity of Resources; Value for money; 
Efficiency/Cost-effectiveness; Trade offs/Choice; Costed options 
………………………………………………………………………………………………………………






6. In Cancer /CHD - Introduction, quote sentences with mentions of the 
following (or similar meaning words/phrases):Scarcity of Resources; Value for 












Are waiting time targets for cancer mentioned? (omitted for HImP documents 
where we looked at the CHD chapter) 
 
8: Other general or specific items of interest for HImP project: 
eg. Quotes of evidence consideration and use specifically 
eg. Quotes on quantifiable targets. 
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
………………………………………………………………………………………………………………
……………………………………………………………………………………………………………… 